Prior high-dose IL-2 therapy (HDIL2) may improve the outcome of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC)
| العنوان: | Prior high-dose IL-2 therapy (HDIL2) may improve the outcome of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC) |
|---|---|
| المؤلفون: | Mario A. Eisenberger, Avivit Peer, Hans J. Hammers, Daniel Keizman, David Sarid, Victoria J. Sinibaldi, Avishay Sella, Michael A. Carducci, Keren Rouvinov, Wilmosh Mermershtain, Henry Hayat, Maya Gottfried, Victoria Neiman, Eliahu Gez, Eli Rosenbaum, Raanan Berger |
| المصدر: | Journal of Clinical Oncology. 32:e15550-e15550 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Oncology, Cancer Research, Il-2 therapy, medicine.medical_specialty, Sunitinib, business.industry, medicine.disease, Renal cell carcinoma, Internal medicine, medicine, In patient, business, medicine.drug |
| الوصف: | e15550 Background: Targeted txs are the tx of choice in most mRCC pts. However, HDIL2 which may produce durable responses in a small percentage of cases, is still an option in carefully selected pt... |
| تدمد: | 1527-7755 0732-183X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::9053a57269174a4c97ce5c48b79978e1 https://doi.org/10.1200/jco.2014.32.15_suppl.e15550 |
| رقم الأكسشن: | edsair.doi...........9053a57269174a4c97ce5c48b79978e1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|